Advertisement

Advertisement

CAMRF Stock Latest News

Camurus’ Acromegaly Drug CAM2029 Resubmission Accepted by U.S. FDA

Company AnnouncementsCamurus’ Acromegaly Drug CAM2029 Resubmission Accepted by U.S. FDA

Camurus AB Earnings Call Highlights Growth And Risks

PremiumCompany Announcements

Camurus AB Earnings Call Highlights Growth And Risks

7d ago

Camurus Delivers Record Product Sales and Strengthens Cash While Deepening Lilly Collaboration

PremiumCompany Announcements

Camurus Delivers Record Product Sales and Strengthens Cash While Deepening Lilly Collaboration

8d ago

Camurus AB (CAMRF) Q2 Earnings Cheat Sheet

PremiumPre-Earnings

Camurus AB (CAMRF) Q2 Earnings Cheat Sheet

9d ago

Camurus Boosts Share Count to Support Employee Incentive Plan

PremiumCompany Announcements

Camurus Boosts Share Count to Support Employee Incentive Plan

23d ago

Camurus hit by FDA manufacturing setback on U.S. acromegaly drug filing

PremiumCompany AnnouncementsCamurus hit by FDA manufacturing setback on U.S. acromegaly drug filing

1M ago

Camurus Targets Real‑World Evidence in New Acromegaly Study With Octreotide Depot

Company Announcements

Camurus Targets Real‑World Evidence in New Acromegaly Study With Octreotide Depot

2M ago

Camurus announces expansion of collaboration with Eli Lilly

The Fly

Camurus announces expansion of collaboration with Eli Lilly

2M ago

Camurus Wins Lilly Option Exercise, Extending Long-Acting Cardiometabolic Drug Deal

PremiumCompany Announcements

Camurus Wins Lilly Option Exercise, Extending Long-Acting Cardiometabolic Drug Deal

2M ago

Camurus Repurchases Series C Shares to Fund Long-Term Incentive Plan

PremiumCompany Announcements

Camurus Repurchases Series C Shares to Fund Long-Term Incentive Plan

2M ago

Camurus AGM Backs Board, Withholds Dividend and Approves New Performance Share Plan

PremiumCompany Announcements

Camurus AGM Backs Board, Withholds Dividend and Approves New Performance Share Plan

2M ago

Camurus Holds Course on 2026 Outlook Despite Softer Q1 Sales

PremiumCompany Announcements

Camurus Holds Course on 2026 Outlook Despite Softer Q1 Sales

2M ago

Camurus Targets Severe Diseases With Long-Acting Drug Innovations

PremiumCompany AnnouncementsCamurus Targets Severe Diseases With Long-Acting Drug Innovations

3M ago

Camurus calls 2026 AGM with capital measures and new incentive plan on agenda

Company Announcements

Camurus calls 2026 AGM with capital measures and new incentive plan on agenda

3M ago

Camurus Expands Share Capital After Employee Stock Option Exercises

Company Announcements

Camurus Expands Share Capital After Employee Stock Option Exercises

4M ago

Camurus Expands Share Capital After Employee Stock Option Exercises

PremiumCompany Announcements

Camurus Expands Share Capital After Employee Stock Option Exercises

5M ago

Camurus Strengthens Executive Team With New Corporate Development Chief

PremiumCompany Announcements

Camurus Strengthens Executive Team With New Corporate Development Chief

5M ago

Camurus AB Earnings Call: Growth, FX and U.S. Push

PremiumCompany Announcements

Camurus AB Earnings Call: Growth, FX and U.S. Push

5M ago

Camurus Posts Strong 2025 Earnings, Expands Long-Acting Endocrine Portfolio

PremiumCompany Announcements

Camurus Posts Strong 2025 Earnings, Expands Long-Acting Endocrine Portfolio

5M ago

CAMRF Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsCAMRF Upcoming Earnings Report: What to Expect?

5M ago

Camurus announces FDA acceptance of NDA resubmission for Oclaiz

The Fly

Camurus announces FDA acceptance of NDA resubmission for Oclaiz

6M ago

Camurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing

Company Announcements

Camurus’ acromegaly drug Oclaiz gains FDA review date after resubmitted US filing

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >